As people age, the balance of benefit and harm shifts for many common drugs, and the AGS Beers Criteria are the standard reference for which medications are potentially inappropriate in adults aged 65 and over. This checker matches a drug name against a curated subset of the 2023 criteria and explains the concern.
How it works
The tool normalises your entry and matches it, case-insensitively, against canonical generic names and common brand aliases in the reference list. A match returns the risk rating — avoid or use with caution — and the evidence-based reason, for example anticholinergic burden, fall risk, hypoglycaemia, or bleeding. The matching is substring-aware so partial entries and brand names still resolve.
Why certain drug classes appear frequently on the list
Several categories of medication are flagged repeatedly because their adverse effect profiles change meaningfully with age:
Anticholinergics — Drugs with strong anticholinergic activity (diphenhydramine, oxybutynin, amitriptyline, and many others) block acetylcholine receptors throughout the body. In older adults, reduced blood-brain barrier integrity means more drug reaches the central nervous system, causing confusion, delirium, memory problems, and worsening of dementia. When multiple anticholinergic drugs are combined, the effects accumulate — a concept known as anticholinergic burden.
Benzodiazepines and sleep aids — Sedative hypnotics slow reaction time and impair balance disproportionately in older adults, increasing fall and fracture risk. Tolerance and dependence develop, yet stopping can be difficult. Shorter-acting alternatives and non-pharmacological interventions are generally preferred.
Long-acting sulfonylureas (such as glibenclamide/glyburide) — These cause prolonged hypoglycaemia, which in older adults can be more severe and harder to recognise than in younger patients. Shorter-acting agents pose less risk.
NSAIDs — Non-steroidal anti-inflammatory drugs increase the risk of gastrointestinal bleeding (especially without a proton pump inhibitor) and can worsen kidney function and fluid retention in older adults.
Using the tool in clinical practice
The Beers Criteria are designed to trigger a structured review, not to mandate stopping. When a drug is flagged, the usual questions are: Is there a safer alternative? Has the patient been on this drug long-term with good tolerance? Are there compelling individual reasons to continue? Is there a monitoring plan in place?
A “use with caution” rating means the drug may still be appropriate but warrants closer attention — reviewing the dose, the duration, potential interactions, and whether monitoring is in place.
Notes and limits
This covers a curated subset of the 2023 AGS Beers Criteria, not the complete list, so a no-match result does not confirm that a drug is safe. Always consult the full published criteria and apply individual clinical judgement alongside a complete medication review.